Forecast horizon — calibration-scored at resolution.
By 2028, SGLT2 inhibitors will be prescribed for ≥70% of eligible HFrEF patients at guideline-adherent cardiology practices.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al. · New England Journal of Medicine · 2020
· openalex W3081830235
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1242
By 2028, quadruple therapy (ACEi/ARNI + BB + MRA + SGLT2i) will be the default HFrEF regimen in US registries.
0.1589
By 2028, ARNI will remain preferred over ACEi as baseline RAS modulation in HFrEF across US and EU guidelines.
0.1682
SGLT2 inhibitor class benefits observed in type 2 diabetes cardiovascular outcome trials will generalize to the broader HFrEF population, including patients without diabetes.
0.2084
The DAPA-HF trial's stated primary conclusion — Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes. — replicates in independent cohorts.
0.2115
The EMPEROR-Reduced trial's stated primary conclusion — Empagliflozin reduces cardiovascular death or heart-failure hospitalization in HFrEF regardless of diabetes status. — replicates in independent cohorts.
0.2147
By 2028, elective PCI rates for stable CAD will have declined by ≥15% in the US post-ISCHEMIA, stabilizing at a new lower baseline.